Halloran Consulting Group Announces Hire of FDA Branch Chief

Halloran hires Sonna Patel-Raman, Ph.D., former Branch Chief of the United States Food and Drug Administration, signifying a new phase of growth and expanded regulatory and device capabilities

BOSTON--(BUSINESS WIRE)--Halloran Consulting Group, Inc. (Halloran) today announced the recent hiring of Sonna Patel-Raman, Ph.D., formerly with the Food and Drug Administration where she served as Branch Chief.

"Halloran's work in the device regulatory space has grown tremendously since our founding, principally because of the rapidly changing regulatory environment"
Halloran is a management consulting company for the life science industry that addresses the obstacles associated with the rising costs of healthcare, drug, and medical device development. In today's rapidly evolving technology and regulatory landscape, Halloran has consistently grown and adapted to meet the changing environment and needs of life science companies in all stages of development.

"Halloran's work in the device regulatory space has grown tremendously since our founding, principally because of the rapidly changing regulatory environment," said Laurie Halloran, President and CEO. "Sonna's arrival at Halloran signifies the next stage in Halloran's growth, and an added depth and dimension to the expertise and guidance we offer clients."

Prior to joining Halloran, Sonna was a branch chief and senior reviewer for over seven years in the Center for Devices and Radiological Health at the United States Food and Drug Administration (FDA). She worked in the Division of Cardiovascular Devices in the Branches of Circulatory Support/Structural Heart Devices. Sonna managed a staff of reviewers and clinicians in the pre-market review of regulatory submissions (PMAs, HDEs, IDEs, 510(k)s, etc.) and provided leadership on a variety of issues related to bench testing, clinical trials (informed consent, design, conduct, and analysis), post-market studies, and compliance. She gained extensive experience in the review of IDEs and PMAs, and preparation for FDA Advisory Panel meetings.

Sonna's hiring at Halloran reflects a larger pattern of growth for the consulting group. Since the second quarter 2013, Halloran has grown over 40%, effectively expanding their regulatory and device capabilities exponentially, at a rate and pattern that is projected to continue through 2014 and into next year.

About Halloran Consulting Group

Halloran is a specialty consulting firm that partners with life science companies to optimize their development. Halloran works with industry organizations of all types, including biotech, pharma, medical device, and service providers, to identify gaps and implement solutions, helping companies achieve excellence in regulatory, quality, and clinical development.

For more information, visit www.hallorancg.com.

Contacts

Halloran Consulting Group, Inc.
Elizabeth Schaul, 781-209-5440
[email protected]
 

Suggested Articles

A TGen-led research team found that increased activity of the gene AEBP1 drives severe liver fibrosis in nonalcoholic steatohepatitis.

Days after announcing its R&D chief was stepping down, Gilead announced it will be buying a few of Novartis’ unwanted early-stage infection assets.

Mallinckrodt is teaming up with Silence Therapeutics to develop an RNAi program aimed at a group of proteins that play a part in promoting inflammation.